Mirum Pharmaceuticals (NASDAQ:MIRM) Director Laurent Fischer purchased 4,650 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average price of $10.60 per share, for a total transaction of $49,290.00.
Shares of NASDAQ:MIRM traded up $0.14 on Friday, hitting $10.02. 10,834 shares of the company’s stock were exchanged, compared to its average volume of 42,818. The stock’s 50-day moving average is $13.00. Mirum Pharmaceuticals has a 1-year low of $9.25 and a 1-year high of $15.50.
Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 28th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($1.83). As a group, research analysts forecast that Mirum Pharmaceuticals will post -3.3 EPS for the current fiscal year.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Further Reading: After-Hours Trading
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.